University of Maryland, Baltimore
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Maryland, Baltimore sits in the top decile of US sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count).
University of Maryland, Baltimore: 560 sponsored US clinical trials, 103 recruiting.
University of Maryland, Baltimore sponsors 560 registered US clinical trials on ClinicalTrials.gov, 103 of them currently recruiting, and 332 completed. 77 of these trials are in Phase 3-4 (later-stage) and 161 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 14 trials.
Top-decile sponsor footprint
University of Maryland, Baltimore ranks in the top decile of sponsors by registered trial count (#62 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
332 of 410 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
560 total, page 5 of 12
Pilot Testing a Digital Intervention to Improve Smoking Cessation in Persons With Serious Mental Illness
NCT04367506
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
NCT04786457
Validation of a Novel Cortical Biomarker Signature for Pain
NCT04241562
Implementation of Function Focused Care in Acute Care
NCT04235374
Translating Peer-to-Peer Support Into a Clinical Setting
NCT04313283
Adjunct VR Pain Management in Acute Brain Injury
NCT04356963
Efficacy of Pathogen Inactivation Strategies for Platelet Transfusion
NCT06535360
Regadenoson Infusion of Marginalized Donor Lungs in an EVLP System
NCT04521569
Trial of Imatinib for Hospitalized Adults With COVID-19
NCT04394416
Shigella CVD 30000: Study of Responses to Vaccination With Shigella Vaccine
NCT04078022
TruGraf Utilization in High IPV Levels
NCT04280276
Targeted Gown and Glove Intervention in Nursing Homes
NCT04200508
Itraconazole Oral Absorption
NCT04035187
Neuroimmune Dysfunction in Alcohol Use Disorder
NCT04210713
Clozapine CHAMPION-ECHO Educational Study to Improve Clozapine Use.
NCT04325386
Home Exercise Program for Homebound Older Adults
NCT04034888
The Effects of Kynurenine Aminotransferase Inhibition in People With Schizophrenia
NCT04013555
Developing and Testing a Brief Intervention for Problem Gambling in Credit Counseling
NCT04064749
Evaluation of Novel Point of Care Coagulation System in Pregnant Women
NCT04301193
Salmonella Conjugates CVD 1000: Study of Responses to Vaccination With Trivalent Invasive Salmonella Disease Vaccine
NCT03981952
Heplisav-B Revaccination for Hepatitis B Vaccine Nonresponders
NCT05791851
CES1 Carriers in the PAPI Study
NCT03188705
Effect of Heat on Rivastigmine TDS Products
NCT03915626
Palliative Care Consultations in the Skilled Nursing Facility (SNF) Setting
NCT03958552
Ideal Pacer Pad Position Study
NCT03898050
Hip Muscle Power, Lateral Balance Function, and Falls in Aging
NCT03731572
Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
NCT04166149
Efficacy of an Interactive Web-Based Home Therapy Program After Stroke
NCT03484182
Service Dog Training Program for Military Veterans With PTSD
NCT03777020
Youth Opioid Recovery Support: Improving Care Systems
NCT04015115
Preop Digifab in CABG to Reduce Ouabain Levels and Prevent AKI
NCT03810417
Prebiotic Treatment in People With Schizophrenia - Pilot Study
NCT03617783
Effects of Early Community Services on Child and Family Development
NCT04019977
The Effect of Donepezil on Glycemic Control in Type II Diabetics
NCT04507438
Robotic Rehabilitation of Cerebral Palsy
NCT02359799
Cholinergic Neurotransmission in Mobility and Cognition in Parkinson Disease
NCT03840837
B/F/TAF Switch Study for HIV-HBV Coinfection
NCT03797014
Pharmacokinetics of Metronidazole Dermal Products
NCT03271983
Dental Carotid Cognitive Study
NCT03755362
SEEK: Dissemination and Implementation
NCT03642327
KCNQ1 Cascade Screening
NCT03783975
Neuromuscular and Biomechanical Control of Lower Limb Loading in Individuals With Chronic Stroke
NCT03694028
Nicotinamide Riboside for Diabetic Neuropathy
NCT03685253
B'More for a Peaceful Motherhood Hypertension Control Study
NCT03741608
Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing
NCT03746002
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
NCT03823911
Blood Donor CVD 9000
NCT03724357
TCMS for the Treatment of Foot Pain Caused By Diabetic Neuropathy
NCT03596203
Antioxidant Use in Diabetes to Reduce Oxidative Stress
NCT03056014
Circuitry-Guided Smoking Cessation in Schizophrenia
NCT03281629
What is open in the University of Maryland, Baltimore pipeline
103 recruiting of 560 indexed (18% open); 332 completed (59%).
Phase mix: 77 late (III/IV) vs 161 early (I/II) (early-phase heavy).
Top condition: Schizophrenia (14 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Maryland, Baltimore: open-pipeline peers nationwide
Peers matched on 560 registered trials and 18% open enrollment, not the therapeutic-area sidebar.
University of Maryland, Baltimore sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 560 trials (± recruiting share)
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 18% open enrollment (± trial volume)
- Abramson Cancer Center at Penn Medicine · 18% recruiting · 402 trials
- Henry Ford Health System · 18% recruiting · 234 trials
- New York Institute of Technology · 18% recruiting · 49 trials
- University of California, San Diego · 18% recruiting · 775 trials
Related
What to do with this University of Maryland, Baltimore page
560 registered trials is a research-attention snapshot, not an endorsement of University of Maryland, Baltimore or any single study.
- 103 of University of Maryland, Baltimore's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition University of Maryland, Baltimore studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Maryland, Baltimore pipeline card: 560 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.